Mylan's shares dropped after it said that delays in launching key new drugs and lower prices for generics in the United States will hurt its profitability this and next year. Fred Katayama reports. Mylan's stock plunged after the maker of Epi …
* Mylan NV - ‍announced it is voluntarily delisting company’s ordinary shares from trading on tel aviv stock exchange * Mylan NV - ‍ delisting of Mylan’s ordinary shares from tase will become effective in three months, on February 12, 2018 ...
StockMarketWire.com - Indivior has confirmed that its US subsidiary, Indivior Inc, together with Monosol Rx, had entered into a settlement agreement with Mylan Pharmaceuticals, Mylan Technologies and Mylan NV resolving patent …
This week, companies like Allergan AGN, Teva TEVA and Mylan MYL were in the limelight. While Mylan and Teva …
The reason is that Mylan’s is an easy scandal to understand, and it has delivered an easy villain in CEO Heather Bresch. News that Bresch low-balled her company’s profit on the EpiPen during her recent Congressional testimony could send …
Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that …
Eleven states require schools to stock epinephrine, according to Food Allergy Research & Education, an allergy advocacy group that counts Mylan as one of its corporate sponsors. A provision in the Federal Aviation Administration …
We believe continued execution and potential business development activity in redomiciled Mylan’s new, more tax-efficient structure could be the keys to future stock performance. Guggenheim’s Louise Chen and Brandon Folkes addressed …